Clinical Trials Logo

Hemodiafiltration clinical trials

View clinical trials related to Hemodiafiltration.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03938285 Active, not recruiting - Clinical trials for Chronic Kidney Disease Requiring Chronic Dialysis

Effect of Hemodiafiltration Plus MCOs on Uremic Toxins Removal

Start date: May 2, 2019
Phase: N/A
Study type: Interventional

Conventional hemodialysis is essential for the treatment of ESRD patients by reducing serum concentration of uremic toxins and correcting fluid overload. Nevertheless, HD removes almost exclusively low-range uremic toxins. Convective methods might reduce complications associated to molecules of medium-range molecular weight. On-Line Hemodiafiltration (OL-HDF) is the result of the combination between convection and diffusion, this modality allows better clearence of middle-range molecules, and protein bound molecules with better hemodynamic tolerance, but at higher cost. In order to solve this problem the middle cut-off membranes were developed, achieving cleareance of molecules between 15,000 to 40,000 Da with low albumin loss. To our knowledge no study has ever evaluated the use of middle cut-off membranes on OL-HDF. This is a prospective, experimental study which will include 12 patients with ESRD that receive OL-HDF treatment on the National Institute of Cardiology "Ignacio Chavez" OL-HDF Unit. They will be divided in 4 groups: high flux HD, extended HD (HDx), OL-HDF, and OL-HDF with medium cut-off membrane.